SANDOZ OLMESARTAN TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

OLMESARTAN MEDOXOMIL

Prieinama:

SANDOZ CANADA INCORPORATED

ATC kodas:

C09CA08

INN (Tarptautinis Pavadinimas):

OLMESARTAN MEDOXOMIL

Dozė:

20MG

Vaisto forma:

TABLET

Sudėtis:

OLMESARTAN MEDOXOMIL 20MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30

Recepto tipas:

Prescription

Gydymo sritis:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0152496002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2017-05-01

Prekės savybės

_Sandoz Olmesartan _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SANDOZ OLMESARTAN
Olmesartan Medoxomil Tablets
20 mg and 40 mg Tablets
USP
Oral
Angiotensin II AT1 Receptor Blocker
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, (Québec), Canada
J4B 1K6
Date of Initial Authorization:
May 1, 2017
Date of Revision:
July 16, 2021
Control No.:249258
_Sandoz Olmesartan _
_Page 2 of 32_
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................................
4
1
INDICATIONS
......................................................................................................................
4
1.1
Pediatrics
.......................................................................................................................
4
1.2
Geriatrics........................................................................................................................
4
2
CONTRAINDICATIONS..........................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................................
5
4
DOSAGE AND ADMINISTRATION
...........................................................................................
5
4.1 Dosing Considerations
........................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
........................................................................
6
4.3 Reconstitution
...................................................................................................................
6
4.4
Administration...................................................................................................................
6
4.5 Missed Dose
......................................................................................................................
6
5
OVERDOSAGE
..............